Scholars@Duke publication: Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer.

Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer.

Publication , Journal Article

Halabi, S; Small, EJ; Vogelzang, NJ

Published in: J Clin Oncol

April 1, 2005

Published version (DOI) Link to item

Duke Scholars

Author Susan Halabi Biostatistics & Bioinformatics, Division of Biostatistics

Published In

J Clin Oncol

DOI

10.1200/JCO.2005.05.890

ISSN

0732-183X

Publication Date

April 1, 2005

Volume

23

Issue

10

Start / End Page

2434 / 2435

Location

United States

Related Subject Headings

Survival Analysis
Prostatic Neoplasms
Prognosis
Oncology & Carcinogenesis
Obesity
Multivariate Analysis
Multicenter Studies as Topic
Male
Humans
Drug Resistance, Neoplasm

Citation

APA

Chicago

ICMJE

MLA

NLM

Halabi, S., Small, E. J., & Vogelzang, N. J. (2005). Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer. J Clin Oncol, 23(10), 2434–2435. https://doi.org/10.1200/JCO.2005.05.890

Halabi, Susan, Eric J. Small, and Nicholas J. Vogelzang. “Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer.” J Clin Oncol 23, no. 10 (April 1, 2005): 2434–35. https://doi.org/10.1200/JCO.2005.05.890.

Halabi S, Small EJ, Vogelzang NJ. Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer. J Clin Oncol. 2005 Apr 1;23(10):2434–5.

Halabi, Susan, et al. “Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer.” J Clin Oncol, vol. 23, no. 10, Apr. 2005, pp. 2434–35. Pubmed, doi:10.1200/JCO.2005.05.890.

Halabi S, Small EJ, Vogelzang NJ. Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer. J Clin Oncol. 2005 Apr 1;23(10):2434–2435.

Published In

J Clin Oncol

DOI

10.1200/JCO.2005.05.890

ISSN

0732-183X

Publication Date

April 1, 2005

Volume

23

Issue

10

Start / End Page

2434 / 2435

Location

United States

Related Subject Headings

Survival Analysis
Prostatic Neoplasms
Prognosis
Oncology & Carcinogenesis
Obesity
Multivariate Analysis
Multicenter Studies as Topic
Male
Humans
Drug Resistance, Neoplasm